| Background:Chronic heart failure(CHF) is a popular clinical syndrome,as well as the terminal stage of many heart diseases.It seriously endanger human health and quality of life,with higher morbidity and death rate.Traditional threpies can only alleviate its symptom,but can't fundamentally restore myocardial cells.Recently researchs show that stem cell can be mobilized to promote myocardial cells regeneration and revascularization,opening up a new way for the treatment of heart failure.However,before the mobilization of stem cells was widely used to clinic,there are still many problems,the adverse effects of cytokine mobilization is still the key factors,which limit their clinical application.Compared with western medicine mobilizing agents,Traditional Chinese medicine has their own unique characteristics,including authentic efficiency,little side effects,multi-target role and currently becoming the hot spots in promoting myocardial regeneration.Most of the current animal trials achieved positive results and demonstrated its unique advantages,but research is still at the initial stage.Clinical research on the mobilization of bone marrow stem cell with traditional chinese medicine both at home and abroad is still rare.Shenfu parenteral solution is one of the commonly used Chinese medicine,with good clinical results for heart failure.This research intends to observe Shenfu parenteral solution impact on cardiac function and to further study its effects on the mobilization of bone marrow stem cells,It is of great significance to further elucidate the mechanism of Chinese medicine threatment for heart failure and promote Chinese medicine developing in the field of stem cell researchObjetive:To investigate the therapeutic effects on cardiac function and mobilization of bone marrow stem cells of chronic heart failure with Shenfu parenteral solution.Methods:63 patients of chronic heart failure caused by coronary heart disease (TCM type of heart and kidney Yang deficiency),were randomly divided into control group with 32 cases(in the routine treatment) and the treatment group with 31 cases (in the routine treatment and Shenfu parenteral solution),after one week treatment, The curative efficiency was measured.Results:1.Comparison of the clinical curative efficiency on two groups of patients:The total efficiency is 93.55%in the treatment group,but 71.88%for the control group,The treatment group is prior to the control group significantly(P＜0.05).2.Comparison of improvement in the patients'symptom integra:After treatment, symptom integra of the two groups ofpatients decreased both(P＜0.01).But the treatment group is prior to the control group significantly(P＜0.01).3.Comparison of improvementin the patients'symptom integra of every symptom:Comparing pre--treatment with post--treatment,the groups of patients'symptom integra of every symptom decreased(P＜0.05或0.01),and palpitation,shortness of breathe,coldness,fatigue,edema of the treatment group's symptom deceased significantly(P＜0.05).4.Comparison of improvement on patient's Cardiac classification:The total efficiency of the treatment group is 90.3%,but 84.3%for the control group,The treatment group has higher efficiency than the control group,but not significant(P＞0.05).5.Comparison of improvement on patient's Cardiac function in ultrasound indicators:After treatment,LVEF,SV,CO,LVESD,LVEDD,FS,E/A ratio were all significantly improved(P＜0.01 or 0.05)than pre—treatment in two groups,but LVEF,SV,CO,LVEDD,FS were significantly improved in the treatment group,better than the control group(P＜0.01 or 0.05).Compared with control group,LVESD and E/A ratio although improved,but statistically with no difference(P＞0.05).6.Comparison of the level of plasma NT-proBNP in two groups:After treatment,the content of NT-proBNP was significantly decreased than before treatment in both groups(P＜0.01),but the treatment group decreased more significantly(P＜0.05). 7.Comparison of the number of peripheral blood CD34~+ stem cells in two groups: The number of peripheral blood CD34~+ stem cells was significantly increased in the treatment group,with a very significant difference(P＜0.01),the number of peripheral blood CD34~+ stem cell was although increased in control group,but statistically with no difference((P＞0.05).The treatment group was prior to the control group(P＜0.01).8.Safety of the two groups:There was no badness response on two groups of patients.After the treatment,liver and kidney function,the results of blood,urine and stool routine test did not change significantly(P＞0.05).Conclusion:Shenfu parenteral solution is clinically a safe and effective traditional Chinese medicine in the treatment of heart failure,It can significantly alleviate clinical symptoms,signs and improve cardiac function of patients with chronic heart failure,Meantime,making content of plasma NT-proBNP significantly decreased.And it can increase the number of peripheral blood CD34~+ stem cells significantly,promote the mobilization of bone marrow stem cells,which can be considered as one of the mechanisms for improving cardiac function. |
PDF Full Text Request